Compare Mongodb Inc (MDB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Summit Therapeutics Inc — how do they compare? Mongodb Inc trades at $380.54 (market cap $29.24B), while Summit Therapeutics Inc trades at $17.33 (market cap $13.71B). The key difference: Mongodb Inc is far larger — about 2.1× Summit Therapeutics Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Summit Therapeutics Inc for 16 Days on average.
| MDB | SMMT | |
|---|---|---|
Market Cap | $29.24B | $13.71B |
Volume | 1,304,995 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $472.29 | $26.38 |
52-Week Low | $225.95 | $12.43 |
Typical Hold Time | 45 Days | 16 Days |
Enterprise Value | $26.86B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $363.03, up 0.64% today, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds with a high P/E of 511.31 and negative net income, though revenue growth remains strong, reaching $2.01B in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
Outlook: Long-term growth potential exists with raised AI-focused targets, but high valuation and profitability challenges pose risks. Analyst consensus is bullish with an $456.76 price target, yet technical indicators and cash flow volatility warrant caution for near-term volatility.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
